Literature DB >> 24496329

Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis.

Irene Marchesi1, Antonio Giordano2, Luigi Bagella3.   

Abstract

Polycomb group proteins represent a global silencing system involved in embryonic development and stem-cell maintenance that regulates the transition from proliferation to differentiation during organogenesis. Two main complexes have been discovered: the polycomb repressive complex (PRC) 1 and 2, able to induce gene silencing by a synergistic mechanism or independently by each other. Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of PRC2, represses gene transcription through the tri-methylation of histone H3 lysine 27. EZH2 deregulation is frequently associated with tumorigenesis, metastatic character, and poor prognosis in various cancer types. This review explores the role of EZH2 in normal development and in carcinogenesis. We reviewed the polycomb-mediated silencing mechanisms, the regulation of EZH2 activity and its recruitment to target genes. We also analyzed the role of EZH2 in normal muscle differentiation and in rhabdomyosarcoma, considering EZH2 blockade as a new strategy for developing specific therapies.

Entities:  

Keywords:  EZH2; cancer epigenetics; differentiation; myogenesis; polycomb group proteins; rhabdomyosarcoma,

Mesh:

Substances:

Year:  2014        PMID: 24496329     DOI: 10.4161/cc.27921

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  21 in total

1.  Amygdalar expression of the microRNA miR-101a and its target Ezh2 contribute to rodent anxiety-like behaviour.

Authors:  Joshua L Cohen; Nateka L Jackson; Mary E Ballestas; William M Webb; Farah D Lubin; Sarah M Clinton
Journal:  Eur J Neurosci       Date:  2017-07-06       Impact factor: 3.386

2.  Functional Proteomic Analysis of Repressive Histone Methyltransferase Complexes Reveals ZNF518B as a G9A Regulator.

Authors:  Verena K Maier; Caitlin M Feeney; Jordan E Taylor; Amanda L Creech; Jana W Qiao; Attila Szanto; Partha P Das; Nicholas Chevrier; Catherine Cifuentes-Rojas; Stuart H Orkin; Steven A Carr; Jacob D Jaffe; Philipp Mertins; Jeannie T Lee
Journal:  Mol Cell Proteomics       Date:  2015-02-13       Impact factor: 5.911

3.  Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.

Authors:  Pooja Hingorani; Edoardo Missiaglia; Janet Shipley; James R Anderson; Timothy J Triche; Mauro Delorenzi; Julie Gastier-Foster; Michele Wing; Douglas S Hawkins; Stephen X Skapek
Journal:  Clin Cancer Res       Date:  2015-10-15       Impact factor: 12.531

4.  Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.

Authors:  Irene Marchesi; Luigi Bagella
Journal:  World J Clin Oncol       Date:  2016-04-10

5.  Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.

Authors:  Amel Dudakovic; Emily T Camilleri; Fuhua Xu; Scott M Riester; Meghan E McGee-Lawrence; Elizabeth W Bradley; Christopher R Paradise; Eric A Lewallen; Roman Thaler; David R Deyle; A Noelle Larson; David G Lewallen; Allan B Dietz; Gary S Stein; Martin A Montecino; Jennifer J Westendorf; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2015-09-30       Impact factor: 5.157

6.  Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice.

Authors:  Amel Dudakovic; Emily T Camilleri; Scott M Riester; Christopher R Paradise; Martina Gluscevic; Thomas M O'Toole; Roman Thaler; Jared M Evans; Huihuang Yan; Malayannan Subramaniam; John R Hawse; Gary S Stein; Martin A Montecino; Meghan E McGee-Lawrence; Jennifer J Westendorf; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2016-10-10       Impact factor: 5.157

7.  Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2.

Authors:  Amel Dudakovic; Rebekah M Samsonraj; Christopher R Paradise; Catalina Galeano-Garces; Merel O Mol; Daniela Galeano-Garces; Pengfei Zan; M Lizeth Galvan; Mario Hevesi; Oksana Pichurin; Roman Thaler; Dana L Begun; Peter Kloen; Marcel Karperien; A Noelle Larson; Jennifer J Westendorf; Simon M Cool; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2020-04-24       Impact factor: 5.157

8.  Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice.

Authors:  Amel Dudakovic; Emily T Camilleri; Christopher R Paradise; Rebekah M Samsonraj; Martina Gluscevic; Carlo Alberto Paggi; Dana L Begun; Farzaneh Khani; Oksana Pichurin; Farah S Ahmed; Ranya Elsayed; Mohammed Elsalanty; Meghan E McGee-Lawrence; Marcel Karperien; Scott M Riester; Roman Thaler; Jennifer J Westendorf; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2018-06-13       Impact factor: 5.157

Review 9.  Pediatric Rhabdomyosarcoma.

Authors:  Jack F Shern; Marielle E Yohe; Javed Khan
Journal:  Crit Rev Oncog       Date:  2015

10.  TAp63gamma is required for the late stages of myogenesis.

Authors:  S Cefalù; A M Lena; B Vojtesek; A Musarò; A Rossi; G Melino; E Candi
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.